Long-Term Use of Mixed-Oil Lipid Emulsion in Adult Home Parenteral Nutrition Patients: A Case Series

• Published in: Nutrition in clinical practice Vol. 33; no. 6; p. 851
• Main Authors: Mundi, Manpreet S, McMahon, Megan T, Carnell, Jennifer J, Hurt, Ryan T
• Format: Journal Article
• Language: English
• Published: United States 01.12.2018
• Subjects: Adult; Alkaline Phosphatase - blood; Bilirubin - blood; Energy Intake; Fat Emulsions, Intravenous - administration & dosage; Fat Emulsions, Intravenous - adverse effects; Fat Emulsions, Intravenous - chemistry; Fatty Acids - administration & dosage; Fatty Acids, Omega-3 - administration & dosage; Fatty Acids, Omega-6 - administration & dosage; Female; Fish Oils - administration & dosage; Glucose - administration & dosage; Humans; Infection - etiology; Intestinal Diseases - etiology; Liver - metabolism; Male; Middle Aged; Olive Oil - administration & dosage; Parenteral Nutrition, Home - methods; Soybean Oil - adverse effects; Time Factors; Triglycerides - administration & dosage; home parenteral nutrition; fatty acids; intravenous fat emulsions; parenteral nutrition; intravenous lipid emulsions; parenteral nutrition solutions
• ISSN: 1941-2452
• DOI: 10.1002/ncp.10014

Despite providing significant benefits, home parenteral nutrition (HPN) can be associated with complications such as infections, intestinal failure-associated liver disease, and metabolic abnormalities. Soybean oil (SO)-based intravenous lipid emulsion (ILE) has been noted to contribute to some of these complications, leading to the development of alternative sources of ILE. Mixed-oil (MO) ILE has recently been approved for use in adults with short-term studies revealing a benefit over SO ILE. Currently there is a paucity of data regarding long-term use in the HPN population. The current study reports our experience with MO ILE in 9 HPN patients. A total of 9 patients (3 women and 6 men) with average age of 48.1 ± 15.1 years and a median HPN use of 9.9 years (9.0 months-30.7 years) were transitioned from SO ILE to MO ILE as a result of intolerance. The 9 patients tolerated MO ILE well for 140.7 ± 29.7 days. The percentage of calories provided through ILE increased from 7.6 ± 6.5% to 18.4 ± 8.2% (P = .003), whereas the dextrose decreased from 66.9 ± 8.4% to 56.9 ± 5.5% (P = .0007). Although statistical significance was not reached, there was a trend toward improvement in alkaline phosphatase from 138.0 (52-884) to 106 (47-512; P = .09). MO ILE was well tolerated in this small cohort and led to improvement in the macronutrient composition of HPN while providing a trend toward improvement in liver studies. These results are promising; however, additional randomized control trials are needed to delineate the true benefit.